Chinese expert's clinical research obtains the achievement Put out the new tactics of lung cancer treatment of later period

Chinese expert's clinical research obtains the achievement Put out the new tactics of lung cancer treatment of later period
Shanghai, November 6 of China News Service (reporter Zeng LiMing) A clinical therapeutic result of study that the Chinese expert launches verifies: Use a gleam of target to treat the epidermis growth factor receptor (EGFR) to the medicine strategic point Lip river for the Buddhist nun The person who didn't get cellule lung cancer of active sudden change, time of surviving of tumour progress does not can improve about 3 times of patient than the regular chemotherapy of first line.
Preside over the Vice President of Guangdong Province the People's Hospital one dragon Professor and today such as Professor such as CaiCun such as Zhou such as head of the department such as tumour such as hospital such as department such as lung such as Shanghai Wu of research announce this research report, claim, the therapeutic tactics that will not be cellule lung cancer that this will change later period; Have the signification for treating the field in China and even international lung cancer.
As have the intersection of Chinese and three clinical research that doctor finish independently reveal strategic point Lip river have life cycle such as progress already for one year for the intersection of Buddhist nun and the intersection of treatment and unique the intersection of type and the intersection of lung cancer and patient, and one year later, in the patient in later period activating sudden change in all epidermis growth factor receptors treated, exceeds half (56%) There are not disease progress, but only 1.7% of rate of the person who accepts chemotherapy. In addition, it is more than two times more than the patient who accept chemotherapy that the proportion that tumour relieves takes place to the patient.
On the 35th European association of internal medicine - oncology held in Italy at the end of last month, two experts' research report arouses the attention from European medicines administration bureau as the theme speech, and drafting so as to support to check it is not the cellule patient in later period when the epidermis growth factor receptor activate sudden change that this medicine is treated as a gleam of form medicine. Professor Wu claims, to nearly 30% of the Asian patients of gene mutation of such unique type take placing, it is undoubtedly a special present.
The main supporter of these research, the madder daughter of pendant of general manager of Shanghai Roche Group warm Chen points out, it is essential to contribution of this achievement for the Chinese expert, not only China but also offers the new healing solution to global doctor.
World Health Organization statistics show, lung cancer has already become the first cancer killer in the world; Global lung cancer and the intersection of bronchus and cancer have illness coming on while being new the example exceeds 1,200,000, about 1,100,000 cases of death every year. The morbidity of Year of China is 3.5/10000, because lung cancer arises the disease is hidden, 70% of the patients have already developed to later period in diagnosis. (End)
|